Drugs / ChAdOx1 85A
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04121494 | Jan 2019 → Aug 2020 | tuberculosis | François Spertini | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01829490 | Jul 2013 → Apr 2016 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03681860 | Jul 2019 → May 2021 | — | University of Oxford | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChAdOx1 85A | “ChAdOx1 85A is an adenoviral vaccine based on a vector that is a chimpanzee adenovirus isolate Y25 expressing the M.tb antigen 85A.” NCT03681860 ↗ |
| Modality | Vaccine | “ChAdOx1 85A vaccination” NCT01829490 ↗ |
| Route | Intramuscular | “ChAdOx1 85A intramuscular injection” NCT01829490 ↗ |